Tag:
Biovail
Latest Headlines
Latest Headlines
Canada bars Biovail founder Melnyk from executive office
Biovail founder Eugene Melnyk ( photo ) will be persona non grata in Canadian public company circles for a while. The Ontario Securities Commission (OSC), Canada's securities regulator, barred Melnyk
Court rules in IntelGenx's favor in Wellbutrin-maker's lawsuit
Quebec-based IntelGenx received a positive ruling Tuesday in a case involving two patents owned by Biovail Laboratories, the maker of the antidepressant Wellbutrin XL. The U.S. District Court of
In wake of chairman's exit, Valeant CFO resigns
'Tis the time of year for executive turmoil, apparently. Valeant Pharmaceuticals ( $VRX ) CFO Peggy Mulligan resigned abruptly, just a week after Chairman Bill Wells departed. This means the company is
Acadia, Biovail end Parkinson's drug deal
Acadia Pharmaceuticals and Biovail, a subsidiary of Valeant Pharmaceuticals, said this morning that they have ended the collaboration agreement on pimavanserin, a drug for Parkinson's. Last year the
Lawmakers object to Biovail-Valeant merger
Maybe the soon-to-merge Valeant Pharmaceuticals and Biovail shouldn't have talked so openly about plans to lay off a big chunk of the combined workforce. On the eve of a shareholder vote to approve
Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100
It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant
Shionogi cutting 350 reps as Biovail boosts layoffs
We've got news for those of you keeping tabs on pharma layoffs. Not only have Valeant and Biovail announced that their planned post-merger job cuts will amount to 25 percent of the combined
Biovail-Valeant combo will cost 25% of all jobs
When the execs at Biovail and Valeant sat down with analysts last June to hype their approaching reverse merger, one of the highlights of their discussion focused on the $175 million in cost
FDA panel backs new epilepsy drug from GSK, Valeant
GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously
Lambda snags Biovail's Toronto CRO
India's Lambda Therapeutic Research has acquired Biovail's Canadian CRO and renamed it Lambda Canada. The 46,000-square-foot research center in Toronto houses 194 beds and a Phase I first-in-human
